Release Details

A scientist inside the laboratory testing specimens

BIOGEN TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS JULY 25, 2023

July 10, 2023

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2023 financial results Tuesday, July 25, 2023, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com. An archived version of the webcast will be available for at least 90 days following the presentation.

About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs